Details for Patent: 10,869,924
✉ Email this page to a colleague
Which drugs does patent 10,869,924 protect, and when does it expire?
Patent 10,869,924 protects INLYTA and is included in one NDA.
Protection for INLYTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty patent family members in sixteen countries.
Summary for Patent: 10,869,924
| Title: | PD-L1 antagonist combination treatments |
| Abstract: | The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer. |
| Inventor(s): | Andrews; Glen Ian (San Diego, CA), Chen; Shihao (Foster City, CA), Di Pietro; Alessandra (Opera, IT), Fontana; David (Clyde Hill, WA), Goldberg; Zelanna (San Diego, CA), Lin; Chia-Yang (Palo Alto, CA), Long; Hua (San Carlos, CA), Martignoni; Marcella (Milan, IT), Nuyten; Dimitry Serge Antoine (San Francisco, CA), Thall; Aron David (San Diego, CA), Woolfson; Adrian (New York, NY) |
| Assignee: | MERCK PATENT GMBH (Darmstadt, DE) PFIZER INC. (New York, NY) |
| Application Number: | 15/736,615 |
|
Patent Claim Types: see list of patent claims | Use; |
Recent additions to Drugs Protected by US Patent 10,869,924
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET | 202324 | Jan 27, 2012 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-3044 | AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,869,924
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-001 | Jan 27, 2012 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,869,924
| PCT Information | |||
| PCT Filed | June 15, 2016 | PCT Application Number: | PCT/US2016/037498 |
| PCT Publication Date: | December 22, 2016 | PCT Publication Number: | WO2016/205277 |
International Family Members for US Patent 10,869,924
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016280003 | ⤷ Sign Up | |||
| Canada | 2989586 | ⤷ Sign Up | |||
| China | 107750166 | ⤷ Sign Up | |||
| European Patent Office | 3310810 | ⤷ Sign Up | |||
| Hong Kong | 1248530 | ⤷ Sign Up | |||
| Israel | 256245 | ⤷ Sign Up | |||
| Japan | 2018522850 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
